Trazodone Adolescent (12 to 17) Dosing

Why Trazodone Is Used Off-Label in Adolescents

Trazodone was approved by the FDA in 1981 for major depressive disorder in adults. No pediatric indication exists. Despite this, it ranks among the most commonly prescribed sleep aids for children and adolescents in the United States, driven by clinician familiarity, low abuse potential, and a side-effect profile that clinicians often consider preferable to benzodiazepines or Z-drugs in younger patients 1.

The Off-Label Prescribing Field

A 2019 analysis of pediatric prescribing trends published in Pediatrics found that trazodone prescriptions for patients aged 5 to 17 increased by over 400% between 2004 and 2017 2. The growth occurred almost entirely in the context of insomnia, not depression. This pattern reflects a broader gap: the FDA has approved very few pharmacologic sleep aids for minors, leaving clinicians to choose between off-label options.

Mechanism Relevant to Adolescent Use

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). At low doses (25 to 100 mg), its strong antagonism of histamine H1 and serotonin 5-HT2A receptors produces sedation without significant serotonin reuptake inhibition 3. This pharmacologic distinction matters. When a clinician prescribes 25 to 50 mg at bedtime for sleep, the drug is functioning primarily as a sedating antihistamine/5-HT2A blocker, not as an antidepressant.

At higher doses (150 mg and above), serotonin reuptake inhibition becomes clinically meaningful, and the drug behaves more like a traditional antidepressant. Adolescent prescribers must keep this dose-dependent pharmacology in mind when setting treatment goals.

Starting Doses for Insomnia in Adolescents

For sleep-onset or sleep-maintenance insomnia in teenagers, the typical approach is conservative. Most pediatric psychopharmacology references recommend beginning at 25 mg orally, taken 30 to 60 minutes before bedtime 4.

Initial Dosing and Titration

If 25 mg is insufficient after 3 to 5 nights, the dose can be increased to 50 mg. Some adolescents respond well at 50 mg, and further increases are rarely needed for insomnia alone. The American Academy of Sleep Medicine (AASM) notes that evidence for trazodone as a hypnotic in any age group is limited, rating it as having insufficient evidence for chronic insomnia even in adults 5. The 2017 AASM clinical practice guideline gave trazodone a "WEAK AGAINST" recommendation for chronic insomnia disorder in adults, a finding that should temper expectations in younger patients.

When Low-Dose Use May Be Appropriate

Despite the weak formal recommendation, clinical practice patterns suggest that low-dose trazodone fills a niche. Adolescents with comorbid anxiety or depression who also report insomnia may benefit from a single agent that addresses both mood and sleep. A 2020 retrospective chart review of 142 adolescents treated with trazodone 25 to 100 mg for insomnia found that 68% of patients reported subjective improvement in sleep quality at 8-week follow-up, with daytime sedation as the most common reason for discontinuation (14% of the sample) 6.

Clinicians should document the rationale for off-label use, confirm that behavioral sleep interventions (sleep hygiene education, cognitive behavioral therapy for insomnia) have been attempted or considered, and obtain informed consent from the adolescent's parent or guardian.

Dosing for Depression in Adolescents

When trazodone is prescribed for adolescent depression rather than insomnia, the dosing framework shifts substantially. Target doses are higher, titration is slower, and monitoring intensity increases.

Starting and Titrating

The standard starting dose for depression is 25 to 50 mg/day. Some clinicians begin at 25 mg at bedtime and increase to 50 mg after one week if the patient tolerates the medication. Titration proceeds in 25 to 50 mg increments every 5 to 7 days. The Maudsley Prescribing Guidelines in Psychiatry (14th edition) suggest that adolescent target doses for depression generally fall between 100 and 150 mg/day, divided into two doses or given as a single bedtime dose 7.

Evidence Limitations

Trazodone has never undergone a large, randomized, placebo-controlled trial for adolescent depression. Mendelson's 2005 review in the Journal of Clinical Psychiatry noted that trazodone's off-label sleep use far outpaced its evidence base, and this observation applies equally to its antidepressant use in minors 1. SSRIs such as fluoxetine (FDA-approved for pediatric depression at age 8+) and escitalopram (approved at age 12+) remain first-line treatments. Trazodone for adolescent depression is typically reserved for patients who have failed or cannot tolerate first-line agents.

Practical Dosing Table

| Indication | Starting Dose | Titration Step | Target Range | Maximum | |---|---|---|---|---| | Insomnia | 25 mg at bedtime | 25 mg every 3 to 5 nights | 25 to 100 mg | 100 mg | | Depression | 25 to 50 mg/day | 25 to 50 mg every 5 to 7 days | 100 to 150 mg/day | 200 mg/day* |

*Some references cite up to 400 mg/day in older adolescents under specialist care, though this exceeds typical practice.

The FDA Black Box Warning and Suicidality Monitoring

Every antidepressant prescribed to a patient under 25 carries the FDA's black box warning about increased risk of suicidal thinking and behavior. This warning applies to trazodone regardless of whether it is prescribed for depression or insomnia 8.

What the Data Show

The FDA's 2004 meta-analysis of 24 short-term trials of antidepressants in children and adolescents found a pooled suicidality risk of 4% on drug versus 2% on placebo. No completed suicides occurred in any of the trials analyzed 8. Trazodone was not among the drugs with the most trial data in this meta-analysis, meaning its individual risk estimate is uncertain.

Required Monitoring Schedule

The FDA recommends face-to-face contact at least weekly for the first four weeks of treatment, every other week for weeks five through twelve, and at the 12-week mark. After that, visits can occur as clinically indicated. The prescriber should use a validated tool, such as the Columbia Suicide Severity Rating Scale (C-SSRS), at each visit 9.

Families should receive clear instructions to contact the prescriber immediately if the adolescent exhibits new or worsening agitation, irritability, impulsivity, or suicidal statements. These symptoms are most likely to emerge during the first one to two months of treatment or during dose changes.

Side Effects Specific to Adolescents

Trazodone's side-effect profile in adolescents overlaps with adults, but certain risks deserve heightened attention in this age group.

Sedation and Daytime Impairment

Excessive sedation is the most common adverse effect. A morning "hangover" feeling can impair school performance. The 2020 retrospective study referenced earlier found that 14% of adolescent patients discontinued trazodone because of persistent daytime drowsiness 6. Dosing earlier in the evening (e.g., 90 minutes before bed rather than at lights-out) or reducing the dose by 25 mg may mitigate this.

Orthostatic Hypotension

Trazodone blocks alpha-1 adrenergic receptors, which can cause dizziness upon standing. Adolescents who are athletic, dehydrated, or taking other blood-pressure-lowering medications are at greater risk. A brief orthostatic vital sign check (lying, then standing blood pressure) at baseline and at dose increases is reasonable clinical practice 10.

Priapism

Trazodone carries a rare but serious risk of priapism (prolonged, painful erection unrelated to sexual arousal). The estimated incidence is between 1 in 6,000 and 1 in 8,000 male patients across all age groups 11. Male adolescents and their guardians must be informed of this risk before starting treatment. Priapism lasting more than four hours is a urologic emergency requiring immediate medical evaluation to prevent permanent tissue damage.

Serotonin Syndrome Risk

Because trazodone modulates serotonin, combining it with other serotonergic medications (SSRIs, SNRIs, tramadol, triptans, dextromethorphan) raises the risk of serotonin syndrome. Dr. Edward Boyer of Harvard Medical School has described serotonin syndrome as "a predictable consequence of excess serotonergic agonism of central nervous system and peripheral receptors" 12. In adolescents already taking an SSRI for depression, adding trazodone for insomnia creates a dual-serotonergic exposure that warrants careful dose management and patient education on symptoms (agitation, tremor, diarrhea, hyperthermia).

Growth, Development, and Long-Term Considerations

Body Weight and Pharmacokinetics

Adolescents between ages 12 and 17 span a wide range of body weights, from approximately 35 kg to over 90 kg. Trazodone is hepatically metabolized via CYP3A4, and its half-life in adults averages 5 to 9 hours 3. Pediatric pharmacokinetic data are sparse. Clinicians often start at the lower end of the dosing range for smaller or younger adolescents (12 to 14 years, under 50 kg) and may use the higher starting dose (50 mg) for older, heavier teens.

Impact on Sleep Architecture

Trazodone increases slow-wave sleep (stages N3) and may reduce REM sleep duration at higher doses. A polysomnographic study in adults found that 100 mg of trazodone increased slow-wave sleep by 56 minutes compared to placebo over an 8-hour recording period 1. Whether this effect is clinically beneficial or detrimental in developing adolescent brains over long treatment durations is unknown. The 2017 American Academy of Pediatrics policy statement on adolescent sleep emphasizes that behavioral interventions remain first-line and that pharmacotherapy should be time-limited when possible 13.

Duration of Treatment

For insomnia, most expert consensus statements recommend reassessing the need for trazodone every 3 to 6 months. A trial taper (reducing by 25 mg every 5 to 7 days) can determine whether the adolescent still needs pharmacologic support. For depression, treatment duration typically follows standard antidepressant guidelines: at least 6 to 12 months of continued therapy after symptom remission before attempting a gradual taper 14.

Drug Interactions to Watch in Adolescents

Adolescent patients often take medications that interact with trazodone's metabolic and pharmacodynamic pathways.

CYP3A4 Inhibitors

Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) can significantly increase trazodone plasma concentrations. The trazodone prescribing information recommends considering a lower trazodone dose when co-administered with a strong CYP3A4 inhibitor 15. In adolescents taking clarithromycin for acne or respiratory infections, this interaction is clinically relevant.

CNS Depressants

Combining trazodone with other CNS depressants (benzodiazepines, antihistamines, opioids, gabapentin) amplifies sedation and respiratory depression risk. The FDA's 2016 boxed warning update on opioid-CNS depressant combinations underscores this concern 15.

QT Prolongation

Post-marketing reports have linked trazodone to QT interval prolongation. The risk is dose-dependent and increases with concurrent use of other QT-prolonging drugs (ondansetron, certain antibiotics). An ECG at baseline may be considered in adolescents with cardiac history or concurrent QT-prolonging medications 10.

Clinical Monitoring Checklist for Prescribers

Structured monitoring reduces risk and improves outcomes. The following schedule reflects FDA guidance combined with pediatric psychopharmacology best practices.

| Timepoint | Assessment | |---|---| | Baseline | C-SSRS, orthostatic vitals, weight, review of concomitant medications, pregnancy test if applicable, informed consent | | Week 1 | C-SSRS, tolerability check (sedation, dizziness), adherence | | Week 2 | C-SSRS, sedation reassessment, dose adjustment if needed | | Week 4 | C-SSRS, orthostatic vitals, sleep diary review or PHQ-A if treating depression | | Week 8 | C-SSRS, efficacy assessment, consider continuing vs. Tapering | | Week 12 | C-SSRS, comprehensive review, plan for maintenance or taper | | Every 3 months thereafter | C-SSRS, growth parameters (height, weight), reassess ongoing need |

Clinicians using trazodone for adolescent insomnia at doses of 25 to 50 mg should still follow the weekly monitoring schedule during the first month, because the black box warning applies regardless of dose or indication.